ArticlePloS one2026
Global, regional, and national burden of nonalcoholic fatty liver disease among adults aged ≥ 45 years: A comprehensive analysis of epidemiological trends and projections to 2035.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause for chronic liver diseases around the globe, disproportionately affecting aging populations. This research focused on the global burden of NAFLD in adults aged 45 and older from 1990 to 2021, with projections extending to 2035.
methodsUsing data from the Global Burden of Disease (GBD) Study between 1990 and 2021, we assessed the incidence, prevalence, mortality and disability-adjusted life years (DALYs) related to NAFLD in adults aged 45 and older in 204 countries and territories. To evaluate the underlying drivers including demographics and lifestyle, Bayesian age-period-cohort (BAPC) modeling was employed.
resultsIn 2021, the worldwide prevalence of NAFLD has reached 48.35 million cases (with a 95% uncertainty interval of 44.23 to 52.36 million). Among individuals aged ≥ 45 years, age-standardized incidence rose by 18.3% (EAPC = 0.53) from 1990 to 2021, while prevalence increased by 24.5% (EAPC = 0.74). Mortality and DALYs also climbed, with Egypt, Mongolia, and Andean Latin America bearing the highest burdens. A bell-shaped Socio-Demographic Index (SDI) correlation emerged, peaking in medium-SDI regions (e.g., North Africa, Middle East). Projections indicate persistent female predominance, with ASIR expected to rise to 826.11 (women) vs. 665.72 (men) per 100,000 by 2035.
conclusionsThis analysis explored the global burden of NAFLD in people aged 45 years and older from 1990 to 2021, demonstrating significant epidemiological changes. Age-standardized incidence and prevalence rates rose by 18.3% and 24.5%, respectively, with the most pronounced burden observed in middle-to-high SDI regions attributable to aging populations. Although women exhibited higher incidence rates, mortality rates remained consistently elevated among men, underscoring unmet intervention needs. Projections to 2035 indicate increasing incidence (particularly in women) alongside moderate declines in mortality and DALYs, underlining the requirement for prevention strategies that are specific to age and gender.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.